Holen Sie sich die Stockscreener-App
0.2963
1.13%
0.0033
Handel nachbörslich:
.30
0.0037
+1.25%
Schlusskurs vom Vortag:
$0.293
Offen:
$0.261
24-Stunden-Volumen:
719.67K
Relative Volume:
0.23
Marktkapitalisierung:
$12.04M
Einnahmen:
$653.40K
Nettoeinkommen (Verlust:
$-20.19M
KGV:
-0.1638
EPS:
-1.8091
Netto-Cashflow:
$-11.11M
1W Leistung:
-34.52%
1M Leistung:
-29.22%
6M Leistung:
-65.79%
1J Leistung:
-76.10%
1-Tages-Spanne:
$0.2609
$0.3171
1-Wochen-Bereich:
$0.2382
$0.4563
52-Wochen-Spanne:
$0.2382
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
Firmenname
Scienture Holdings Inc
Sektor
Branche
Telefon
(800) 261 0281
Adresse
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, POM, HKPD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.2963 | 12.04M | 653.40K | -20.19M | -11.11M | -1.8091 |
HITI
High Tide Inc
|
2.31 | 203.04M | 452.61M | -35.30M | 13.25M | -0.3863 |
PETS
Petmed Express Inc
|
2.29 | 49.01M | 182.67M | -64.87M | -22.92M | -3.1193 |
POM
Pomdoctor Ltd Adr
|
0.2447 | 29.17M | 0 | 0 | 0 | 0.00 |
HKPD
Cellyan Biotechnology Co Ltd
|
0.569 | 13.37M | 0 | 0 | 0 | 0.00 |
Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten
Exclusive: Penny stock Scienture reports revenue surge, expanding market access in 2025 - msn.com
SCNX PE Ratio & Valuation, Is SCNX Overvalued - Intellectia AI
Scienture reports 216% revenue growth, gross margin expansion By Investing.com - Investing.com Australia
Scienture Holdings Inc (MEDS) Reports FY2025 Earnings - AlphaStreet
Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings - news.alphastreet.com
Scienture Holdings, Inc. 2025 Annual Report: Key Risks, Forward-Looking Statements, and Business Overview - Minichart
Scienture Holdings: Q4 Earnings Snapshot - MarketScreener
Scienture reports 216% revenue growth, gross margin expansion - Investing.com
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update - The Globe and Mail
Scienture Holdings 10-K: $0.43M Revenue, $(2.70) EPS — ARBLI™ Launch Drives Growth - TradingView
Scienture’s blood pressure drug drove 216% growth; overdose spray up next - Stock Titan
Scienture Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Scienture Holdings (NASDAQ: SCNX) outlines CNS, CVS drug launches and pipeline - Stock Titan
EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025 - Benzinga
Scienture Holdings Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Aug Decliners: Will Scienture Holdings Inc be affected by tariffsAnalyst Downgrade & Verified Entry Point Signals - baoquankhu1.vn
If You Invested $1,000 in Scienture Holdings, Inc (SCNX) - Stock Titan
Gap Down: What are analysts price targets for Scienture Holdings Inc2026 Technical Overview & Expert Approved Trade Ideas - baoquankhu1.vn
Exclusive: Scienture expands reach for opioid overdose treatment, with deals covering 60% of US institutional market - MSN
Scienture secures GPO deals for naloxone nasal spray By Investing.com - Investing.com Nigeria
Scienture Holdings regains compliance with Nasdaq listing requirements - MSN
Scienture Holdings files to sell 2.1M shares for holders - MSN
Scienture (SCNX) Co-CEO adds stock grants and converts preferred into common - Stock Titan
Scienture files $200M mixed securities shelf - MSN
Scienture secures GPO deals for naloxone nasal spray - Investing.com India
Scienture Holdings (SCNX) Co-CEO granted 500,000 restricted shares - Stock Titan
SCNX Expands Market Reach with New GPO Agreements - GuruFocus
SCIENTURE Broadens Commercial Access for REZENOPY, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - Bitget
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - The Manila Times
High-dose overdose spray REZENOPY set to reach 5,000 US care sites - Stock Titan
EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market - Benzinga
Total current assets of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
What makes Scienture Holdings Inc. stock attractive to growth funds2025 AllTime Highs & High Conviction Buy Zone Alerts - Naître et grandir
Why Scienture Holdings Inc. stock remains a top recommendationMarket Activity Recap & Daily Profit Focused Stock Screening - Naître et grandir
Is Scienture Holdings Inc. stock a top pick in earnings seasonWeekly Trade Review & Proven Capital Preservation Tips - Naître et grandir
Why Is Scienture Stock Rising Today? - Stocktwits
SCNX SEC FilingsScienture Holdings, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SCNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SCNX Earnings History & Surprises | EPS & Revenue Results | SCIENTURE HOLDINGS INC (NASDAQ:SCNX) - ChartMill
Aug Spikes: What is Scienture Holdings Incs market position2025 Big Picture & Community Supported Trade Ideas - baoquankhu1.vn
SCNX Should I Buy - Intellectia AI
Scienture Holdings, Inc.: Target Price Consensus and Analysts Recommendations | | US80880X1046 - marketscreener.com
Scienture Holdings, Inc.: Revenue and Earnings Analysts Forecasts Revisions | | US80880X1046 - marketscreener.com
SCNX Technical Analysis & Stock Price Forecast - Intellectia AI
Scienture Holdings, Inc.: Revenue and Earnings Analysts Forecasts Revisions | SCNX | US80880X1046 - marketscreener.com
Scienture (NASDAQ:SCNX) Coverage Initiated by Analysts at Maxim Group - Defense World
Maxim Group Initiates Coverage on Scienture Holdings (SCNX) with a 'Buy' Rating | SCNX Stock News - GuruFocus
Maxim Group Initiates Coverage of Scienture Holdings (SCNX) with Buy Recommendation - Nasdaq
Maxim Group Initiates Coverage on Scienture (NASDAQ:SCNX) - National Today
What are analysts’ price targets for Scienture Holdings Inc.2025 Year in Review & Fast Gaining Stock Reports - mfd.ru
Aug Movers: What is Scienture Holdings Incs market positionWeekly Gains Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Finanzdaten der Scienture Holdings Inc-Aktie (SCNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
5.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):